As noted in two previous reports from the Coronary Drug Project,1,2 physicians face a difficult dilemma concerning pharmacologic therapy of hyperlipidemia-hyperlipoproteinemia in an attempt to prevent first or recurrent episodes of clinical coronary heart disease. It is known that susceptibility to premature coronary heart disease is directly related to serum levels of cholesterol, and of low-density and very-low-density lipoproteins. It is also known that elevated serum levels of lipids-lipoproteins frequently can be influenced over long periods of time by available drugs. However, answers to key questions about these pharmaceutical agents are lacking. Do they prevent coronary heart disease and prolong life? Are they reasonably safe in long-term usage?
The Coronary Drug Project—a nationwide collaborative study sponsored by the National Heart and Lung Institute—is the most extensive effort ever undertaken to answer these questions with regard to men who have already experienced one or more episodes of myocardial infarction.1-5
The Coronary Drug Project: Findings Leading to Discontinuation of the 2.5-mg/day Estrogen Group. JAMA. 1973;226(6):652–657. doi:10.1001/jama.1973.03230060030009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: